Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to achieve durable responses in first remission or in the relapsed or refractory settings. Addition of rituximab to chemotherapy for FL has been shown to improve survival. The impact of prior therapy with rituximab upon the effectiveness of high-dose therapy (HDT) and ASCT in patients with FL is unknown. We retrospectively reviewed consecutive patients with FL who underwent HDT and ASCT. Patients were categorized according to prior therapy with rituximab. Outcomes were compared between groups in all patients and in a well-matched subset. In all 35 patients received prior rituximab and 71 rituximab-naive patients were analyzed. The rituximab-naive group had a median overall survival (OS) that was not reached during follow-up, with a median relapse-free (RFS) survival of 49.9 months. The prior rituximab group also did not reach median OS and had a median RFS of 24.6 months. Survivals were not significantly different in this group or in the well-matched subset. In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL.
Introduction
Follicular lymphoma (FL) is the most common type of indolent lymphoma and second most common among all non-Hodgkin's lymphomas. 1 Its incidence is increasing, and 85-90% of patients have advanced stage disease at the time of diagnosis. While treatment strategies have evolved, FL is still not considered curable by conventional chemotherapies. The development of rituximab in the last decade has improved the outcome of patients diagnosed with this disease. The first trials which led to the approval of rituximab for use in FL were aimed at patients in the relapsed setting. 2, 3 Subsequently, frontline use of rituximab was addressed in a number of studies. In several randomized prospective trials undertaken by the German Low-Grade Lymphoma Study Group (GLSG), response rates, progression-free and overall survival (OS) rates were superior in patients receiving rituximab containing regimens compared with chemotherapy alone. 4, 5 Despite therapeutic advances, FL continues to be a disease that is characterized by a relapsing course. Highdose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) is a strategy that has been employed in an attempt to improve outcomes in this disease. The European CUP (Chemotherapy, Unpurged-, Purged-stem cell) trial in which patients with relapsed FL were randomized to either chemotherapy (CHOP-like) or HDT and ASCT (with, or without purged autograft) was undertaken to determine the impact of high-dose therapy (HDT) and ASCT on OS. Despite slow accrual and early termination, the trial demonstrated a benefit in progression-free survival and OS for patients undergoing HDT followed by ASCT. 6 All of the trials published to date have examined the use of HDT and ASCT in FL patients treated prior to the introduction of rituximab as a component of first-line therapy for this disease. Moreover, comparisons have only been made to non-rituximab containing chemotherapy regimens. The effectiveness of HDT and ASCT in patients whose first-line therapy includes rituximab is unknown. Most recent studies have demonstrated improved relapse or progressionfree survival for patients receiving rituximab as a component of initial therapy, when compared with those not receiving this agent. It is therefore possible that patients whose disease progresses after rituximab-based therapy may be less readily 'salvaged' by other approaches such as HDT and ASCT. To test this hypothesis, we performed a retrospective analysis of the transplant database at our institution.
Methods

Patient selection
Patients undergoing HDT and ASCT for FL between 1994 and 2004 were identified from the Cleveland Clinic Foundation Transplant Center's Unified Transplant Database. All patients were treated on protocols approved by the Institutional Review Board and provided informed consent. Totally, 128 patients were identified. Nineteen patients who received rituximab as part of salvage therapy but not initial therapy prior to ASCT and three patients who received bone marrow autografts were excluded. The remaining 106 patients were divided into two groups based on their prior exposure to rituximab; those who were rituximab-naive (71 patients) and those who received prior rituximab as part of planned therapy (35 patients). All 106 patients had at least one prior chemotherapy regimen, and all were treated with the same preparative regimen, which consisted of busulfan, etoposide and cyclophosphamide (busulfan 14 mg kg
À1
, etoposide 60 mg kg À1 and cyclophosphamide 120 mg kg
). Peripheral blood hematopoietic stem cells were mobilized using GCSF (10 mg kg day ). Stem cell collection was performed on a COBE spectra leukopheresis machine (COBE, Denver, CO, USA). None of the patients received maintenance rituximab.
Statistical analysis
Categorical variables were compared between rituximabnaive and prior rituximab groups using the w 2 test, and summarized as frequency counts and percentages. Continuous variables were compared using either the t-test or Wilcoxon rank-sum test. The mean and s.d. are reported if the t-test was used. Otherwise, the median and range are reported. OS and relapse-free survival (RFS) were the primary endpoints; both were calculated relative to the transplant date. Outcomes were estimated using the Kaplan-Meier method and compared between groups using the log-rank test. Several methods were used to assess the prognostic effect of rituximab, adjusting for other factors. Univariate Cox proportional hazards analysis was used to assess rituximab and ten other study variables: age, gender, stage, histological grade according to the International Working Formulation, number of prior chemotherapy regimens, prior radiation therapy, disease status at transplant, IPI at transplant, interval from diagnosis to transplant and CD34 þ dose. Variables that differed between rituximab-naive and prior rituximab groups at Pp0.10 and that were prognostic on univariate analysis at Pp0.10 were included with rituximab in a multivariate Cox proportional hazards analysis. Next, propensity-score methods were used to make additional assessments of rituximab with adjustments for other factors. 7 A logistic regression model containing the ten non-rituximab variables was used to calculate the probability of receiving rituximab for each patient (propensity score). This propensity score was included with rituximab in a multivariate Cox proportional hazards analysis using data from all 106 patients. Next, the propensity score was used to identify well-matched groups of rituximab-naive and prior rituximab, 8 which resulted in 22 well-matched patients per group. Because the resulting groups are similar except for the use of rituximab, outcomes were compared between groups using the log-rank test and univariate Cox proportional hazards analysis. Analyses were carried out using SAS software (SAS Institute, Inc., Cary, NC, USA) Unless otherwise noted, all statistical tests were two-sided, and Pp0.05 was used to indicate statistical significance.
Results
Patient characteristics according to rituximab therapy are shown in Table 1 . Characteristics between the rituximabnaive group and prior rituximab group overall were similar, with major differences being age (mean 50 vs 55 years, , respectively, Po0.001), and length of follow-up (median 77.1 vs 22.4 months, respectively, Po0.001). Overall and RFSs according to prior exposure to rituximab are shown in Figures 1 and 2 . The rituximabnaive group had a median RFS of 49.9 months, while that for the prior rituximab group was 24.6 months (P ¼ 0.47). The median OS of both the rituximab-naive and priorrituximab groups were not reached during follow-up (P ¼ 0.28).
Propensity analysis identified 22 patients from the rituximab-naive group who were well-matched to 22 patients from the prior rituximab group. Table 2 summarizes the characteristics of this group of patients. Differences in age and CD34 þ dose between groups were not statistically significant (P ¼ 0.67 and 0.94, respectively). Median OS for the rituximab-naive group and the prior rituximab group were not reached and were not statistically different (P ¼ 0.31). The RFS for this well-matched cohort were also found to have no significant difference, with the rituximab-naive group's median time of 51.7 months and prior rituximab group being 24. Prior rituximab on ASCT in follicular lymphoma TY Kang et al assesses rituximab among 44 well-matched patients. Model 3 assesses rituximab for all 106 patients adjusting for age and CD34 þ dose (the variables which were prognostic and which differed between groups), while Model 4 adjusts for the propensity score. All four methods suggest increased hazard of death for prior rituximab relative to rituximabnaive (hazard ratios ranging from 1.47 to 1.84) and also increased hazard of relapse or death (hazard ratios ranging from 1.24 to 1.40). However, none of these findings achieved statistical significance (P ¼ 0.16-0.54). The results are summarized in Table 3 .
Discussion
The role of ASCT following HDT and its impact on OS in FL remains uncertain. Because of its indolent nature and the fact that traditional treatments do little to improve the OS of patients, studies in FL have shown that an expectant management approach for patients who are clinically asymptomatic results in equivalent OS compared to early initiation of therapy. [9] [10] [11] While patients who begin treatment when they become symptomatic from their disease usually have responses to therapy, they inevitably relapse and require further salvage regimens. The tendency for remission duration to become shorter with successive therapies has been well documented, 12 and in an attempt to overcome this trend, HDT and ASCT has been investigated for patients with relapsed FL in several studies. In separate studies, investigators at Dana Farber Cancer Institute (DFCI) and St Bartholomew's Hospital examined long-term outcome of patients with relapsed FL who underwent HDT and ASCT. At DFCI, with a follow-up of 8 years, disease free survival (DFS) and OS were found to be 42 and 66%, respectively. At St Bartholomew's, freedom from recurrence and survival were 63 and 69%. 13, 14 Although these studies have suggested that remission duration is improved with the use of ASCT, the effect on OS is less clear. In the European CUP trial, Schouten et al. 6 addressed this in patients with relapsed FL who were randomized to a CHOP-like regimen or HDT followed by ASCT (with or without stem cell purging). In a series of 140 patients accrued in an international, multi-institute setting, they found that the hazard ratios for RFS and OS were 0.30 (P ¼ 0.0037) and 0.72 (P ¼ 0.072), in favor of ASCT. HDT followed by ASCT in the first-line treatment of FL has also been studied. While earlier trials appear to show benefit, a more recent study with mature follow-up does not. The French group Groupe d'Etude des Lymphomes de l'Adulte (GELA) randomized 401 patients to CHVP plus interferon vs CHOP followed by HDT (TBI) and ASCT. With 7.5 years of follow-up, there was no difference in OS or eventfree survival.
The introduction of monoclonal antibody therapies such as rituximab has increased uncertainty regarding the role of HDT and ASCT. More recently, the use of conventional chemotherapy in conjunction with rituximab has demonstrated encouraging results in the frontline setting. In the interim analysis of a phase III European Organization for Research and Treatment of Cancer (EORTC) trial, improvements in response rates and progression-free survival were demonstrated. 15 In the GLSG studies, rituximab was used in combination with chemotherapy to treat chemotherapy-naive patients. Using cyclophosphamide, vincristine and prednisone as the therapeutic backbone, Marcus et al. 4 randomized 321 patients to treatments with, or without rituximab. The group with rituximab therapy had a significantly longer median time-to-treatment failure (27 vs 7 months, Po0.0001). In a similar study, Hiddemann et al. 5 evaluated 428 patients randomized to CHOP with, or without rituximab. Not only was time-tofailure improved, but response rate, treatment-free interval and OS were also significantly better. These studies demonstrated that rituximab, as part of their first-line therapy, resulted in significantly improved outcome.
While the addition of rituximab to the initial treatment of FL is clearly beneficial, its effect on HDT and ASCT is unknown. Patients who relapse after rituximab-based therapy are speculated to have more adverse disease and therefore a worse outcome after HDT and ASCT. Our analysis tries to address this important question. In an attempt to reduce confounding factors and streamline the analysis, we restricted our study to include patients whose initial therapy included rituximab, rather than trying to include those who may have received salvage rituximab therapy in second-, third-, fourth-line or after. Likewise, since the majority of the patients undergoing transplantation were autografted using mobilized peripheral stem cells, the three patients with bone marrow autografts who would otherwise have met our other inclusion criteria were excluded.
Our results appear to show that the outcome of these patients is no different from patients who were not exposed to rituximab in the frontline setting, and that the KaplanMeier plot of the two groups is overlapping. Using multivariate models adjusting for variables that differ between the groups, while there appears to be a suggestion that rituximab use may be favorable, there was neither a statistically significant nor a trend toward a difference in the outcomes between these two groups. We understand that there are some major limitations to our study, one of the biggest being the small number of patients in our database. Although the confidence intervals do overlap, they are also quite large, given the small number of patients, and therefore a small but clinically significant difference could potentially be missed. While we do not view the results as conclusive evidence that rituximab therapy does not compromise HDT and ASCT, we view this pilot study as a hypothesis generating one and a potential adjunct to future studies attempting to identify the role rituximab plays in the setting of indolent lymphoma therapy and transplantation. It is also important to point out that because this study was a registrybased analysis, it was therefore restricted to evaluating the effect rituximab has on HDT and ASCT. The impact of rituximab on other aspects of salvage therapy is therefore not addressed here.
Despite the limitations of relatively small patient numbers and shorter duration of follow-up for patients receiving prior rituximab in this study, the results appear to show that the prior use of rituximab in FL therapy does not compromise the effectiveness of HDT and ASCT. Moreover, it has been thought that rituximab as a targeted therapy may additionally impart benefit in the peri-transplantation period. Rituximab has now been proposed as an agent for the in vivo purging of stem cells in an attempt to deal with minimal residual disease. 16 Its use has been shown to produce no adverse effects either in stem cell collection or in the immediate or chronic complication rates during transplantation. 17 Others have shown that maintenance rituximab following chemotherapy may improve progression-free survival. 18 With more patients being exposed to rituximab, further studies will be needed to help elucidate rituximab's effects on patients who subsequently undergo HDT and ASCT. While large trials performed in randomized, prospective settings may be difficult given the ubiquitous use of rituximab as part of therapy for follicular lymphoma, studies based on larger transplant databases from multiple institutions can help confirm our findings.
